A consultant for vaccines and immunization, Dragoslav Popovic, on Aug. 24 asked what had happened to the announced construction of a plant in Serbia that would produce Chinese vaccines, considering that Health Minister Zlatibor Loncar had said that Chinese shots would be made in Vrsac-based Hemorfarm, owned by German Stada.
“What has happened to a plant to produce Chinese vaccines if Hemofarm is to make them? It is a surprising announcement by Minister Loncar. So far, Hemofarm has not had vaccines in its portfolio, neither has Stada,” Popovic told portal Autonomija. Hemofarm could not provide any comment on Loncar’s statement that everything would be “shortly” ready in the pharmaceutical company.
In mid-May, President Aleksandar Vucic published on his Instagram a video clip of a future plant for vaccine production in Serbia along with an explanation saying that this was how a Serbian vaccine maker should look like, which was to be built with partners from the UAE and China.
Popovic recalled that a majority stake in Hemofarm was owned by a foreign company, noting that neither Serbian science nor the development of technology or the Torlak Institute of Virology, Vaccines and Sera could benefit from any investment in such a company.